respiratory syncytial virus

August 15, 2023

Study finds most infants receiving ICU-level care for RSV had no underlying medical condition

A Vanderbilt study found that most infants admitted to the intensive care or high acuity unit for respiratory syncytial virus (RSV) infections during fall 2022 were previously healthy and born at term.

James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)
August 4, 2023

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.
April 24, 2023

Study finds early RSV infection linked to significantly increased risk of asthma in children

A Vanderbilt study has found that RSV infection in the first year of life is associated with a significantly increased risk of asthma in children.

March 9, 2023

Study finds RSV may evade vaccines via rapid mutation

A Vanderbilt study concluded that RSV’s ability to mutate rapidly to escape detection by the body’s immune system makes it more challenging to design and develop vaccines that can stop it from spreading.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.
July 21, 2022

Study explores role RSV plays in later asthma development

A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development

February 28, 2022

Study finds azithromycin use during RSV not useful in preventing recurrent wheezing, may cause harm

Vanderbilt research on the impact of the antibiotic azithromycin during severe respiratory syncytial virus (RSV) bronchiolitis overwhelmingly support current national bronchiolitis guidelines, which recommend against antibiotics during acute bronchiolitis due to lack of effect on the acute illness.